SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The move strengthens GBL’s clinical-stage presence in the United States
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Subscribe To Our Newsletter & Stay Updated
